文献速递前列腺癌

根治性局部治疗后生化复发的挽救治疗:系统综述、Meta分析与网状Meta分析

Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-09-13

该系统综述与网状Meta分析检索截至2023年10月的文献,纳入19项研究共9117例根治性局部治疗后生化复发的非转移性前列腺癌患者。成对Meta分析显示,挽救性放疗联合激素治疗较单纯放疗显著改善无转移生存(HR 0.69,95%CI 0.57-0.84,p<0.001)。治疗排名分析中,放疗策略里前列腺床放疗联合选择性淋巴结放疗和雄激素剥夺治疗(ADT)对无转移生存最有效,激素策略中恩扎卢胺联合ADT对无转移生存和总生存获益最大。

要点

  • 挽救性放疗联合激素治疗较单纯放疗显著改善无转移生存(HR 0.69,95%CI 0.57-0.84,p<0.001)。
  • 放疗策略中,前列腺床放疗联合选择性淋巴结放疗和ADT对无转移生存最有效。
  • 激素策略中,恩扎卢胺联合ADT对无转移生存和总生存获益最大。

核心结论

  • 基于本分析,前列腺床放疗联合选择性盆腔照射和ADT是适合的根治性前列腺切除术后生化复发患者的首选治疗。
  • 其余患者或放疗后复发者,尤其高危生化复发者,应考虑ADT联合雄激素受体信号抑制剂(ARSI)。

研究设计与样本

  • 系统综述、Meta分析与网状Meta分析,检索PubMed、Scopus和Web of Science数据库(截至2023年10月)。
  • 纳入报告挽救治疗疗效的随机对照试验(RCT)和前瞻性研究,共19项研究、9117例患者。
  • 6项试验分析根治性前列腺切除(RP)后基于放疗的策略,10项分析RP±放疗或单纯放疗后基于激素的策略,3项分析其他药物。

主要发现

  • 成对Meta分析显示,挽救性放疗联合激素治疗较单纯放疗显著改善无转移生存(HR 0.69,95%CI 0.57-0.84,p<0.001)。
  • 治疗排名分析中,基于放疗的策略里,选择性淋巴结放疗联合ADT对无转移生存最有效。
  • 基于激素的策略里,恩扎卢胺联合ADT对无转移生存和总生存获益最大。

临床怎么用

  • 作者认为,前列腺床放疗联合选择性盆腔照射和ADT是适合的RP后生化复发患者的首选治疗。
  • 作者认为,其余患者或放疗后复发者,尤其高危生化复发者,应考虑ADT联合ARSI。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent advancements in the management of biochemical recurrence (BCR) following local treatment for prostate cancer (PCa), including the use of androgen receptor signaling inhibitors (ARSIs), have broadened the spectrum of therapeutic options. We aimed to compare salvage therapies in patients with BCR after definitive local treatment for clinically non-metastatic PCa with curative intent. METHODS: In October 2023, we queried PubMed, Scopus, and Web of Science databases to identify randomized controlled trials (RCTs) and prospective studies reporting data on the efficacy of salvage therapies in PCa patients with BCR after radical prostatectomy (RP) or radiation therapy (RT). The primary endpoint was metastatic-free survival (MFS), and secondary endpoints included progression-free survival (PFS) and overall survival (OS). RESULTS: We included 19 studies (n = 9117); six trials analyzed RT-based strategies following RP, ten trials analyzed hormone-based strategies following RP ± RT or RT alone, and three trials analyzed other agents. In a pairwise meta-analysis, adding hormone therapy to salvage RT significantly improved MFS (HR: 0.69, 95% CI: 0.57-0.84, p < 0.001) compared to RT alone. Based on treatment ranking analysis, among RT-based strategies, the addition of elective nodal RT and androgen deprivation therapy (ADT) was found to be the most effective in terms of MFS. On the other hand, among hormone-based strategies, enzalutamide + ADT showed the greatest benefit for both MFS and OS. CONCLUSIONS: The combination of prostate bed RT, elective pelvic irradiation, and ADT is the preferred treatment for eligible patients with post-RP BCR based on our analysis. In remaining patients, or in case of post-RT recurrence, especially for those with high-risk BCR, the combination of ADT and ARSI should be considered.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Matsukawa A, Yanagisawa T, Fazekas T, et al. Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 39266730. doi:10.1038/s41391-024-00890-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。